Abstract #3894

Improved the performance of differential diagnosis between Prostate Cancer and Benign Prostate Hyperplasia using APT and mDIXON-Quant

Xue Ren¹, Ailian Liu¹, Lihua Chen¹, Shuang Li¹, Yue Wang¹, Jiazheng Wang², Qingwei Song¹, Sun Peng², Renwang Pu³, and Yuanfei Li¹

¹The First Affiliated Hospital of Dalian Medical University, Dalian, China, ²Philips Healthcare, Beijing, China, ³First Affiliated Hospital of Dalian Medical University, Dalian, China

Accurate identifying prostate cancer (PC) from benign prostatic hyperplasia (BPH) is of great significance for timely and proper treatment. Amide proton transfer (APT) is a novel MRI method sensitive to several kinds of cancers. mDIXON-Quant is a powerful quantitive technique for simultaneous fat quantification and R2* mapping, which can reflect the tissue contents and properties. This study aims to assess the diagnostic performance of APT and mDIXON-Quant on differentiating prostate cancers and benign prostate hyperplasia. Results indicate that the combination of APT and mDIXON-Quant can enhance the differential diagnosis of PC and BPH.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.